Avellino Lab AvaGen
Avellino Lab has launched AvaGen, a test that assesses risk for keratoconus and other corneal distrophies, with full nationwide availability in the US. According to the company, the test examines more than 2,000 variants in 75 keratoconus-related genes. The assay reports a keratoconus risk score that is intended to inform decisions around the use and timing of US Food and Drug Administration-approved cross-linking treatment, which can halt disease progression and preserve vision. AvaGen results can also influence an eye care professional's choice of refractive surgery options.
For corneal dystrophies, the test determines the presence of any of the 70 TGFBI gene variants and provides a conclusive diagnosis of corneal dystrophy subtypes, such as epithelial basement membrane, granular and lattice disease distinctions, Reis-Bucklers, Schnyder and Theill-Behnke.